Robert Chess, Director at NEKTAR THERAPEUTICS (NKTR), sold 28,558 shares at $16.02 ($457K) on 2021-09-09, disclosed to the SEC on 2021-09-10.
Seasonal sale ($457k) by Director — this insider has traded NKTR in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.00 | 8,000 | $128K | 28.0% |
| 2 | $16.02 | 10,279 | $165K | 36.0% |
| 3 | $16.02 | 10,279 | $165K | 36.0% |
| Total | $16.01 avg | 28,558 | $457K | 100% |
| Filing → |
| TWST | SELL | 2026-02-18 | $105K | — | Filing → |
| TWST | SELL | 2025-02-11 | $312K | — | Filing → |
| TWST | SELL | 2025-01-10 | $250K | — | Filing → |